Results 191 to 200 of about 257,346 (272)

Control of Type 1 and Type 2 Errors in Configural Frequency Analysis. [PDF]

J Pers Oriented Res
von Weber S, von Eye A.
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Accuracy of Deep Learning in Diagnosing Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis. [PDF]

J Med Internet Res
Yang H, Wu Y, Wu T, Ji J, Lei S, Xu W.
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Recalibrating evidence: a cautionary note on the use of post hoc thresholds in IPD meta-analyses. [PDF]

Eur Thyroid J
Arredondo Montero J.
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Microplastics in Sediments Originating from Abandoned, Lost or Discarded Fishing Gear (ALDFG) in Coastal Areas of the Valencian Community. [PDF]

Biology (Basel)
Romeo L, Perdichizzi A, Profeta A, Vitale D, Franch VC, Casu M, Spinelli A.   +6 more
europepmc   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Assessing the performance of artificial intelligence models in evaluating inflammatory skin disease severity: a systematic review and meta-analysis. [PDF]

Br J Dermatol
Cai ZR, Kim J, Rezaei SJ, Chen ML, Touma F, Zhu C, Onyeka S, Fonjungo F, Omiye JA, Krakowski I, Nwandu L, Biossonnette R, Ko JM, Linos E.   +13 more
europepmc   +1 more source

High‐Resolution Deep Learning Dixon Magnetic Resonance Imaging of the Sacroiliac Joints Is Noninferior to Standard Magnetic Resonance Imaging in Patients With Suspected Axial Spondyloarthritis

Arthritis &Rheumatology, EarlyView.
Objective To compare the multisequence standard magnetic resonance imaging (sMRI) protocol of the sacroiliac joints with a single high‐resolution deep learning–reconstructed Dixon sequence (DL‐Dixon) in patients with suspected axial spondyloarthritis (axSpA). Methods Seventy‐six patients with chronic low back pain and suspected axSpA underwent clinical,
Dominik Deppe, Mariam Koka, Fabian Proft, Sevtap Tugce Ulas, Kay‐Geert Hermann, Denis Poddubnyy, Mikhail Protopopov, Henriette Baum, Hildrun Haibel, Mehrgan Shahryari, Valeria Rios Rodriguez, Jens Vogel‐Claussen, Torsten Diekhoff   +12 more
wiley   +1 more source